Vitamin B3 Shows Promise Against Fatty Liver Disease in New Research
Scientists discover vitamin B3 can target a key genetic driver of fatty liver disease, offering hope for 30% of people affected globally.
Summary
Fatty liver disease affects 30% of people worldwide and has lacked effective treatments. Researchers at UNIST identified microRNA-93 as a key genetic driver that worsens the condition by disrupting fat metabolism in liver cells. When they tested 150 FDA-approved drugs, vitamin B3 (niacin) emerged as the most effective at reducing this harmful microRNA. In mice, vitamin B3 treatment significantly reduced liver fat accumulation and improved overall liver function. Since vitamin B3 is already widely available and considered safe, this discovery could lead to new treatment approaches for millions of people with fatty liver disease.
Detailed Summary
Metabolic-associated fatty liver disease (MASLD) affects roughly 30% of people globally, yet effective treatments have remained elusive. New research from an international team led by UNIST has identified a specific genetic mechanism driving the disease and discovered that a common vitamin could potentially treat it.
The researchers pinpointed microRNA-93 (miR-93) as a central regulator in fatty liver disease. This small RNA molecule is found at unusually high levels in both human patients and animal models with the condition. The team discovered that miR-93 promotes fat buildup, inflammation, and liver scarring by suppressing SIRT1, a gene crucial for proper fat metabolism in liver cells.
To test potential treatments, the scientists screened 150 FDA-approved drugs for their ability to reduce miR-93 levels. Vitamin B3 (niacin) proved most effective. In mouse studies, vitamin B3 treatment dramatically lowered miR-93 levels while boosting SIRT1 activity, leading to improved fat processing and better overall liver function.
This finding is particularly significant because vitamin B3 is already widely available, well-studied, and considered safe for long-term use. It's currently prescribed for treating high cholesterol, giving it an established safety profile that could accelerate clinical development.
The research represents the first clear identification of miR-93's role in fatty liver disease progression. While promising, these results come from animal studies and require human clinical trials to confirm effectiveness and optimal dosing for liver health.
Key Findings
- MicroRNA-93 drives fatty liver disease by suppressing SIRT1, a key fat metabolism gene
- Vitamin B3 effectively reduces harmful microRNA-93 levels in liver cells
- Mice treated with vitamin B3 showed significantly less liver fat accumulation
- Gene editing to block microRNA-93 improved insulin sensitivity and liver function
- Vitamin B3 outperformed 149 other FDA-approved drugs in targeting this pathway
Methodology
This is a research news report from ScienceDaily covering peer-reviewed research published in Metabolism: Clinical and Experimental. The study comes from established institutions (UNIST, Pusan National University) with government funding support, suggesting credible methodology involving both animal models and drug screening approaches.
Study Limitations
Results are primarily from mouse studies and require human clinical trials for validation. The article doesn't specify optimal vitamin B3 dosing for liver benefits or potential side effects. Long-term safety and effectiveness in humans with fatty liver disease remain unproven.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.